Price: $ 1295
BMI View: High inflation, currency devaluation, import and foreign currency controls, as well as other structurally distorting policies in Venezuela will continue to trouble the country's pharmaceutical market in Q413. We expect the market to grow below nominal GDP levels between 2012 and 2017, and experience a contraction in real growth terms. Low-cost generic drugs made in Cuba will continue to be an important resource for Venezuela to meet its local medicine demand. Headline Expenditure Projections ? Pharmaceuticals: VEB43.5bn (US$10.1bn) in 2012 to VEB53.3bn (US$8.8bn) in 2013; +22.6% in local currency terms and -13.3% in US dollar terms. Forecast downwards from Q313. ? Healthcare: VEB86.7bn (US$20.2bn) in 2012 to VEB107.1bn (US$17.6bn) in 2013; +23.5% in local currency terms and - ...
Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/278773.html
No comments:
Post a Comment